Physician profile
Viktorija Overiene
NPI 1952500803
$636.17
in general payments reported to CMS, 2019-2025
14 companies · $68.23 in 2025
The $68.23 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $118 · 2021: $108 · 2022: $103 · 2023: $12.93 · 2024: $49.27 · 2025: $68.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.18 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.18 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116.04 | 2019-2025 | |
| Lilly USA, LLC | $108.91 | 2019-2023 | Taltz |
| Astrazeneca Pharmaceuticals LP | $75.69 | 2024-2025 | Enhertu, Saphnelo |
| Horizon Therapeutics Plc | $50.74 | 2019-2021 | |
| Amgen INC. | $46.12 | 2020-2024 | Tavneos |
| Sanofi-Aventis U.S. LLC | $45.95 | 2019 | |
| Janssen Biotech, INC. | $36.47 | 2020-2022 | |
| Ucb, INC. | $29.57 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $28.03 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $25.87 | 2020 | |
| Genentech USA, INC. | $25.53 | 2019-2020 | |
| Genzyme Corporation | $19.68 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.76 | 2019 | |
| Glaxosmithkline, LLC. | $11.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viktorija Overiene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.